Detection of Enterococcal Surface Protein Gene (esp) and Amplified Fragment Length Polymorphism Typing of Glycopeptide-Resistant Enterococcus faecium during its Emergence in a Greek Intensive Care Unit

Journal of Clinical Microbiology

Volumn 41, Issue 12, 2003, Pages 5742-5746

  Routsi, C ^a,b   Platsouka, E ^b   Willems, R J L ^c   Bonten, M J M ^d   Paniara, O ^b   Saroglou, G ^a   Roussos, C ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b EVANGELISMOS HOSPITAL   (Greece)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CHLORAMPHENICOL; CIPROFLOXACIN; GENTAMICIN; GLYCOPEPTIDE; RIFAMPICIN; STREPTOMYCIN; TEICOPLANIN; TETRACYCLINE; VANCOMYCIN;

ADULT; AGED; AMPLIFIED FRAGMENT LENGTH POLYMORPHISM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL VIRULENCE; BACTERIUM ISOLATION; CLINICAL ARTICLE; ENTEROCOCCAL SURFACE PROTEIN GENE; ENTEROCOCCUS FAECIUM; GENE IDENTIFICATION; GENETIC SIMILARITY; GREECE; HUMAN; INTENSIVE CARE UNIT; NONHUMAN; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; BACTERIAL PROTEINS; ENTEROCOCCUS FAECIUM; GRAM-POSITIVE BACTERIAL INFECTIONS; GREECE; HUMANS; MEMBRANE PROTEINS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PHYLOGENY; POLYMORPHISM, GENETIC; RANDOM AMPLIFIED POLYMORPHIC DNA TECHNIQUE; TREATMENT OUTCOME; VARIATION (GENETICS);

BACTERIA (MICROORGANISMS); ENTEROCOCCUS; ENTEROCOCCUS FAECIUM; POSIBACTERIA;

EID: 0348109497     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.41.12.5742-5746.2003     Document Type: Article

References (18)

1. Antonishyn, N. A., R. R. McDonald, E. L. Chan, G. Horsman, C. E. Woodmansee, P. S. FalK and C. G. Mayhall. 2000. Evaluation of fluorescence-based amplified fragment length polymorphism analysis for molecular typing in hospital epidemiology: comparison with pulsed-field gel electrophoresis for typing strains of vancomycin-resistant Enterococcus faecium. J. Clin. Microbiol. 38:4058-4065.
2. Bonten, M. J. M., R. Willems, and R. A. Weinstein. 2001. Vancomycin-resistant enterococci: why they are here, and where do they come from? Lancet Infect. Dis. 1:314-325.
3. Centers for Disease Control and Preventation. National nosocomial infections surveillance (NNIS) system report, data summary from January 1990-May 1999, issued June 1999. Am. J. Infect. Control 27:520-532.
4. Clark, N. C., R. C. Cooksey, B. C. Hill, J. M. Swenson, and F. C. Tenover. 1993. Characterization of glycopeptide-resistant enterococci from U.S. hospitals. Antimicrob Agents Chemother. 37:2311-2317.
5. Coque, T. M., R. Willems, R. Canton, R. Del Campo, and F. Baquero. 2002. High occurrence of esp among ampicillin-resistant and vancomycin-suscep-tible Enterococcus faecium clones from hospitalized patients. J. Antimicrob. Chemother. 50:1035-1038.
6. Dutka-Malen, S., S. Evers, and P. Courvalin. 1995. Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR. J. Clin. Microbiol. 33:24-27.
7. Jett, B. D., M. M. Huycke, and M. S. Gilmon. 1994. Virulence of enterococci. Clin. Microbiol. Rev. 7:462-478.
8. Kim, W. J., R. A. Weinstein, and M. Hayden. 1999. The changing molecular epidemiology and establishment of endemicity of vancomycin resistance in enterococci at one hospital over a 6-year period. J. Infect. Dis. 179:163-171.
9. National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; 5th ed. Approved standard M7-A5. National Committee for Clinical Laboratory Standards, Wayne, Pa.
10. Pegues, D. A., C. F. Pegues, P. L. Hibbert, D. S. Ford, and D. C. Hooper. 1997. Emergence and dissemination of a highly vancomycin-resistant vanA strain of Enterococcus faecium at a large teaching hospital. J. Clin. Microbiol. 35:1565-1570.
11. Platsouka, E. D., H. Dimopoulou, V. Miriagou, and O. Paniara. 2000. The first clinical isolates of Enterococcus faecium with the VanA phenotype in a tertiary Greek hospital. J. Antimicrob. Chemother. 46:1039-1040.
12. Routsi, C., E. Platsouka, O. Paniara, E. Dimitriadou, G. Saroglou, C. Roussos, and A. Armaganidis. 2000. Enterococcal infections in a Greek intensive care unit: a 5-year study. Scand. J. Infect. Dis. 32:275-280.
13. Schouten, M. A., A. Voss, and J. A. Hoogkamp-Korstanje. 1999. Antimicrobial susceptibility patterns of enterococci causing infections in Europe. Antimicrob. Agents Chemother. 43:2542-2546.
14. Shankar, V., A. S. Baghdayan, M. M. Huycke, G. Lindah, and M. S. Gilmore. 1999. Infection-derived Enterococcus faecalis strains are enriched in esp, a gene encoding a novel surface protein. Infect. Immun. 67:193-200.
15. Vergis, E. N., N. Shankar, J. W. Chow, M. K. Hayden, D. R. Snydman, M. J. Zervos, P. K. Linden, M. M. Wagener, and R. R. Muder. 2002. Association between the presence of enterococcal virulence factors gelatinase, hemolysin, and enterococcal surface protein and mortality among patients with bacteremia due to Enterococcus faecalis. Clin. Infect. Dis. 35:570-575.
16. Vos, P., R. Hogers, M. Bleeker, M. Reijans, T. van de Lee, M. Hornes, A. Frijters, J. Pot, J. Peleman, M. Kuiper, et al. 1995. AFLP: a new technique for DNA fingerprinting. Nucleic Acids Res. 23:4407-4414.
17. Willems, R. J. L., J. Top, N. van den Braak, A. van Belkum, H. Endtz, D. Mevious, E. Stobberingh, A. van den Bogaard, and J. D. A. van Embden. 2000. Host specificity of vancomycin-resistant Enterococcus faecium. J. Infect. Dis. 182:816-823.
18. Willems, R. J. L., W. Homan, J. Top, M. van Santen-Verheuvel, D. Tribe, X. Manzioros, C. Gaillard, C. M. Vandenbroucke, E. M. Mascini, E. van Kregten, J. D. van Embden, and M. J. Bonten. 2001. Variant esp gene as a marker of a distinct genetic lineage of vancomycin-resistant Enterococcus faecium spreading in hospitals. Lancet 357:853-855.